Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human study of MMV390048. The study will evaluate the safety, tolerability
and pharmacokinetic properties of escalating single and multiple doses of MMV390048 when
administered to healthy male volunteers and female volunteers of non-childbearing potential.
In addition, the effect of food on the pharmacokinetics and tolerability of MMV390048 will be
investigated.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Technology Innovation Agency, South Africa University of Cape Town